Strides Pharma, Amneal Pharmaceuticals partner to launch Icosapent ethyl capsules

Strides Pharma, Amneal Pharmaceuticals partner to launch Icosapent ethyl capsules

Strides Pharma Science Limited (“Strides”) has joined forces with Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) to introduce Icosapent ethyl acid soft gel capsules to the market. This new product, referencing VASCEPA®, is set to be commercialized by Amneal starting in the fourth quarter of 2023. The in-licensing of this product from Strides, a global pharmaceutical […]

Strides Pharma receives FDA approval for Icosapent Ethyl Capsules

Strides Pharma receives FDA approval for Icosapent Ethyl Capsules

Strides Pharma Science Limited (Strides) has achieved a significant milestone by announcing the United States Food & Drug Administration (USFDA) approval of Icosapent Ethyl Capsules 0.5 gram and 1 gram. This approval comes through its wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore. The newly approved product seamlessly integrates into Strides’ portfolio of authorized […]

Amarin bags Vascepa FDA approval for reducing cardiovascular risk

Amarin bags Vascepa FDA approval for reducing cardiovascular risk

Vascepa FDA approval : New Jersey-based Amarin has secured approval from the US Food and Drug Administration (FDA) for a new indication and label expansion for Vascepa (icosapent ethyl) capsules. The FDA has now approved Vascepa as an adjunctive (secondary) therapy to cut down the risk of cardiovascular events in adults having elevated triglyceride levels, […]